Heron Therapeutics, Inc. /De/
HRTX Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.30
KIRA · Stoqly’s AI analyst, in plain words
- Heron Therapeutics, Inc. /De/ had $155M of revenue in fiscal 2025, up 7.4% on the year before. Over five years, revenue changed +11.8% a year on average.
- Its operating margin was −1.6%, up 6.4 pts: of every 100 in sales, about −2 is left after running the business.
- Heron Therapeutics, Inc. /De/ lost $20.2M in fiscal 2025.
- Free cash flow was −$27.9M in fiscal 2025, −18.0% of revenue.
Market cap
$57.2M
P/E
—
Revenue
$155M
Net income
−$20.2M
Free cash flow
−$27.9M
Operating margin
−1.6%
Heron Therapeutics, Inc. /De/ in 30 seconds · fiscal 2025
Are sales growing?
+7.4%
Yes. Sales grew 7.4% last year.
Does it make a profit?
−13.0%
No. It lost money last year.
Does profit turn into cash?
−18.0%
No. It spent more cash than it brought in.
How healthy are the accounts?
2 / 8
Weak. It passes 2 of 8 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Heron Therapeutics, Inc. /De/ does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Feb 26, 2026
- Legal name
- HERON THERAPEUTICS, INC. /DE/
- CIK
- 0000818033
Heron Therapeutics, Inc. /De/ · HRTX
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $86.3M | $108M | $127M | $144M | $155M |
| Revenue growth | −2.6% | 24.7% | 18.0% | 13.6% | 7.4% |
| Gross margin | 46.7% | 49.0% | 48.8% | 73.2% | 73.3% |
| Operating margin | −252.3% | −162.2% | −87.1% | −8.0% | −1.6% |
| Net income | −$221M | −$182M | −$111M | −$13.6M | −$20.2M |
| Net margin | −255.6% | −169.1% | −87.0% | −9.4% | −13.0% |
| Diluted EPS | −$2.24 | −$1.67 | −$0.80 | −$0.09 | −$0.12 |
| Cash | |||||
| Cash from operations | −$203M | −$147M | −$58.8M | −$22.5M | −$27.6M |
| Capital expenditure | $3.0M | $1.8M | $1.5M | $1.7M | $0.3M |
| Free cash flow | −$206M | −$149M | −$60.3M | −$24.2M | −$27.9M |
| FCF margin | −239.0% | −138.1% | −47.5% | −16.8% | −18.0% |
| Share count change | −99.9% | 110,434.0% | 26.9% | 10.4% | 9.4% |
| Debt and strength | |||||
| Cash and short-term investments | $158M | $84.9M | $80.4M | $59.3M | $46.6M |
| Shareholders' equity | $77.6M | $13.6M | −$34.0M | −$33.7M | $14.3M |
| Current ratio | 3.6x | 2.5x | 2.4x | 2.3x | 2.5x |
| Interest coverage | −90.4x | −70.6x | −28.6x | −1.9x | −0.3x |
| Returns and quality | |||||
| Return on equity | −140.5% | −399.4% | — | — | — |
| Return on tangible equity | −284.5% | −1,341.2% | — | — | −140.9% |
| Piotroski F-score | 4 | 3 | 3 | 3 | 2 |
| Altman Z'' | −17.7 | −24.7 | −28.2 | −24.0 | −21.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Heron Therapeutics, Inc. /De/ · HRTX
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.30 a share, the company is worth $57.2M.
Source: SEC EDGAR XBRL filings (CIK 0000818033). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.